TLIS RSI Chart
Last 7 days
-3.4%
Last 30 days
6.3%
Last 90 days
7.8%
Trailing 12 Months
33.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 2.8M | 2.9M | 2.2M | 2.1M |
2022 | 4.4M | 4.8M | 5.4M | 4.8M |
2021 | 17.5M | 16.8M | 7.6M | 8.2M |
2020 | 0 | 0 | 0 | 10.9M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Nov 18, 2021 | baker bros. advisors lp | bought | 218,250 | 4.365 | 50,000 | - |
Aug 13, 2021 | ramakrishnan ramesh | sold | -210,665 | 7.66 | -27,502 | - |
Aug 13, 2021 | ramakrishnan ramesh | acquired | 78,532 | 1.5 | 52,355 | - |
May 17, 2021 | scott randal w. | bought | 111,210 | 10.11 | 11,000 | - |
May 14, 2021 | scott randal w. | bought | 91,440 | 10.16 | 9,000 | - |
Feb 17, 2021 | popovits kimberly j | acquired | - | - | 22,041 | - |
Feb 17, 2021 | popovits kimberly j | bought | 84,800 | 16.00 | 5,300 | - |
Feb 17, 2021 | popovits kimberly j | acquired | - | - | 209,790 | - |
Feb 17, 2021 | scott randal w. | acquired | - | - | 1,390,060 | - |
Feb 17, 2021 | scott randal w. | bought | 5,000,000 | 16.00 | 312,500 | - |
Which funds bought or sold TLIS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | added | 71.16 | 2,792 | 5,556 | -% |
May 15, 2024 | ADAR1 Capital Management, LLC | new | - | 2,625 | 2,625 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -6.17 | 750 | 8,111 | -% |
May 15, 2024 | DME Capital Management, LP | new | - | 1,304,200 | 1,304,200 | 0.06% |
May 15, 2024 | PRELUDE CAPITAL MANAGEMENT, LLC | unchanged | - | 19,406 | 130,620 | 0.01% |
May 15, 2024 | BAKER BROS. ADVISORS LP | unchanged | - | 660,820 | 4,447,830 | 0.06% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -74,679 | - | -% |
May 14, 2024 | Qube Research & Technologies Ltd | unchanged | - | 3.00 | 18.00 | -% |
May 13, 2024 | UBS Group AG | reduced | -5.51 | 105 | 1,051 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | added | 5.41 | 20,010 | 104,077 | -% |
Unveiling Talis Biomedical Corporation's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Talis Biomedical Corporation)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.0M | 3.7M | -0.09 | 0.28 |
Talis Biomedical Corporation News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Revenue | -100.0% | - | 195,000 | 140,000 | 581,000 | 1,218,000 | 257,000 | 796,000 | 572,000 | 3,187,000 | 858,000 | 218,000 | 117,000 | 7,000,000 | 233,000 | 9,486,000 | 820,000 | 399,000 |
Gross Profit | - | - | - | - | - | - | - | -440,000 | -730,000 | -334,000 | - | 218,000 | 117,000 | 7,000,000 | - | - | - | - |
Costs and Expenses | -3.1% | 14,190,000 | 14,651,000 | 17,111,000 | 16,972,000 | 20,215,000 | 28,370,000 | 27,582,000 | 27,845,000 | 36,154,000 | - | - | - | - | - | - | - | - |
Operating Expenses | - | - | - | - | - | - | - | 26,346,000 | 26,543,000 | 32,633,000 | 29,378,000 | 38,633,000 | 64,478,000 | 67,520,000 | 44,415,000 | 39,069,000 | 10,844,000 | 7,794,000 |
S&GA Expenses | 76.5% | 11,651,000 | 6,602,000 | 8,803,000 | 6,410,000 | 6,399,000 | 10,796,000 | 8,825,000 | 9,178,000 | 11,930,000 | 12,316,000 | 12,792,000 | 9,983,000 | 7,327,000 | 5,305,000 | 3,058,000 | 2,660,000 | 2,080,000 |
R&D Expenses | -68.5% | 2,533,000 | 8,041,000 | 8,302,000 | 10,555,000 | 13,796,000 | 15,242,000 | 17,521,000 | 17,365,000 | 20,703,000 | 17,062,000 | 25,841,000 | 54,495,000 | 60,193,000 | 39,110,000 | 36,011,000 | 8,184,000 | 5,714,000 |
Net Income | 3.2% | -13,035,000 | -13,460,000 | -15,682,000 | -15,034,000 | -17,831,000 | -26,929,000 | -26,021,000 | -27,011,000 | -33,051,000 | -28,654,000 | -38,418,000 | -64,472,000 | -60,492,000 | -44,196,000 | -29,514,000 | -10,046,000 | -7,374,000 |
Net Income Margin | 7.7% | -26.81 | -29.06 | -34.37 | -30.09 | -34.40 | -23.49 | -21.20 | -26.29 | -37.58 | -23.44 | -27.43 | -11.80 | -8.22 | - | - | - | - |
Free Cashflow | 42.9% | -6,427,000 | -11,264,000 | -11,214,000 | -14,759,000 | -16,489,000 | -13,592,000 | -21,682,000 | -22,212,000 | -44,265,000 | -41,728,000 | -75,507,000 | -33,832,000 | -23,183,000 | - | - | - | - |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -12.9% | 82.00 | 95.00 | 107 | 123 | 133 | 169 | 194 | 222 | 231 | 266 | 303 | 380 | 403 | 198 |
Current Assets | -8.4% | 71.00 | 78.00 | 90.00 | 102 | 116 | 133 | 150 | 174 | 201 | 236 | 278 | 354 | 391 | 189 |
Cash Equivalents | -6.3% | 72.00 | 77.00 | 88.00 | 98.00 | 113 | 130 | 144 | 165 | 188 | 233 | 274 | 313 | 348 | 173 |
Inventory | - | - | - | - | - | - | - | 2.00 | 2.00 | 3.00 | - | - | - | - | - |
Net PPE | -46.3% | 2.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 7.00 | 10.00 | 11.00 | 11.00 | 10.00 | 10.00 | 10.00 | 9.00 |
Liabilities | 1.0% | 26.00 | 26.00 | 26.00 | 27.00 | 23.00 | 43.00 | 42.00 | 45.00 | 28.00 | 32.00 | 44.00 | 86.00 | - | 16.00 |
Current Liabilities | 8.0% | 9.00 | 9.00 | 8.00 | 9.00 | 11.00 | 13.00 | 11.00 | 14.00 | 15.00 | 19.00 | 31.00 | 73.00 | 47.00 | 16.00 |
Shareholder's Equity | -18.0% | 57.00 | 69.00 | 82.00 | 96.00 | 110 | 127 | 152 | 177 | 203 | 234 | 259 | 294 | 356 | - |
Retained Earnings | -2.4% | -553 | -539 | -526 | -510 | -495 | -477 | -451 | -425 | -397 | -364 | -336 | -297 | -233 | -172 |
Additional Paid-In Capital | 0.1% | 610 | 609 | 608 | 607 | 606 | 605 | 603 | 602 | 601 | 599 | 595 | 592 | 590 | 64.00 |
Shares Outstanding | 1639.1% | 32.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | - | - |
Float | - | - | - | - | 8,152 | - | - | - | 7,342 | - | - | - | 181,704 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | 43.4% | -6,427 | -11,357 | -11,144 | -14,274 | -16,465 | -13,543 | -20,822 | -22,013 | -43,758 | -40,741 | -74,748 | -33,410 | -22,485 | -36,691 | -32,798 | -11,953 | -5,582 |
Share Based Compensation | -41.1% | 601 | 1,020 | 1,072 | 1,076 | 1,183 | 1,282 | 1,296 | 1,245 | 1,545 | 3,168 | 2,476 | 1,791 | 1,772 | 1,564 | 1,031 | 407 | 681 |
Cashflow From Investing | -67.7% | 30.00 | 93.00 | -70.00 | -485 | -24.00 | -49.00 | -860 | -199 | -507 | -987 | -759 | -422 | -698 | -2,406 | -5,458 | -218 | -119 |
Cashflow From Financing | - | 2.00 | - | - | - | 33.00 | - | 92.00 | - | 314 | 670 | 1,002 | -722 | 233,479 | 122,174 | 13,040 | 111,535 | 5.00 |
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Total revenue, net | $ 73 | $ 1,218 |
Operating expenses: | ||
Cost of products sold | 6 | 20 |
Research and development | 2,533 | 13,796 |
Selling, general and administrative | 11,651 | 6,399 |
Total operating expenses | 14,190 | 20,215 |
Loss from operations | (14,117) | (18,997) |
Other income, net | 1,082 | 1,166 |
Net loss and comprehensive loss | $ (13,035) | $ (17,831) |
Net loss per share - basic | $ (7.15) | $ (9.84) |
Net loss per share - diluted | $ (7.15) | $ (9.84) |
Weighted average shares used in the calculation of net loss per share, basic | 1,822,050 | 1,812,723 |
Weighted average shares used in the calculation of net loss per share, diluted | 1,822,050 | 1,812,723 |
Grant | ||
Revenue | $ 0 | $ 1,081 |
Product revenue, net | ||
Revenue | $ 73 | $ 137 |
Condensed Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 70,337 | $ 76,732 |
Accounts receivable, net | 6 | 50 |
Prepaid expenses and other current assets | 827 | 901 |
Total current assets | 71,170 | 77,683 |
Property and equipment, net | 1,628 | 3,030 |
Operating lease right-of-use-assets | 8,154 | 12,419 |
Other long-term assets | 1,542 | 1,542 |
Total assets | 82,494 | 94,674 |
Current liabilities: | ||
Accounts payable | 3,619 | 1,339 |
Accrued compensation | 1,958 | 3,836 |
Accrued liabilities | 992 | 715 |
Operating lease liabilities, current portion | 2,902 | 2,882 |
Total current liabilities | 9,471 | 8,772 |
Operating lease liabilities, long-term portion | 16,339 | 16,786 |
Total liabilities | 25,810 | 25,558 |
Commitments and contingencies (Note 6) | ||
Stockholders' equity: | ||
Common stock, $0.0001 par value; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 1,822,153 and 1,821,986 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 0 | 0 |
Additional paid-in capital | 609,677 | 609,074 |
Accumulated deficit | (552,996) | (539,961) |
Total stockholders' equity | 56,684 | 69,116 |
Total liabilities and stockholders' equity | 82,494 | 94,674 |
Series 1 Convertible Preferred Stock | ||
Stockholders' equity: | ||
Series 1 convertible preferred stock, $0.0001 par value - 60,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 29,863,674 shares issued and outstanding as of March 31, 2024 and December 31, 2023; aggregate liquidation preference of $3 as of March 31, 2024 and December 31, 2023 | $ 3 | $ 3 |